In this contest, THRβ-selective thyromimetic TG68 has been found to provide beneficial effects by mimicking thyroid hormone in its ability to reduce hepatic fat accumulation in the absence of unwanted toxic effects, mainly mediated by THRα, representing an attractive candidate for the treatment of primarily lipid-related metabolic disorders, including dyslipidemia and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) [24]. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.